Page 2 - Eric Liebler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders April 26, 2021 08:00 ET | Source: electroCore, Inc. electroCore, Inc. Rockaway, New Jersey, UNITED STATES ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) --  -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigat...

2  “gammaCore (nVNS) is the only treatment option, drug or device, that is currently available for the acute and preventive treatment of migraine in adolescents,” said Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “With their interest in technology and desire to avoid prescription drugs, gammaCore represents a unique treatment for adolescents with migraine. We would like to thank the Division of Neuromodulation and Physical Medicine Devices and their colleagues at the FDA for their efforts to review and clear the expanded label for gammaCore." The label expansio...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to ... electroCoreFebruary 9, 2021 GMT ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on...

Published: Feb 02, 2021 ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore. Stroke is t...